Search

Introduction: The extent of burnout among clinical and non-clinical academics during the COVID-19 pandemic is not well gauged and necessitates further attention. This study was designed to determine the prevalence of burnout among academics in the International Islamic University Malaysia (IIUM), Kuantan campus, and the associated sociodemographic and occupational-related factors. Methods: We conducted a cross-sectional study between March and May 2021 using questionnaires adapted from Copenhagen Burnout Inventory and General Stressor Questionnaire at the IIUM, Kuantan campus. Results: 57 clinical and 93 non-clinical academics responded to the survey. The prevalence of significant burnout was 49%. Compared to non-clinical academics, clinical academics had a significantly higher proportion of burnout with a p-value of <0.001, particularly in work-related, student-related, and superior-related burnout domains, with a p-value of 0.004, <0.001, and 0.006, respectively. Factors significantly associated with burnout among our cohort were clinical work, chronic illness, and gender, each with an odds ratio of 2.72 (95% CI = 1.01,7.34), 2.81 (95% CI = 1.14, 6.92), and 4.86 (95% CI = 2.15, 10.9). Conclusion: Burnout was highly prevalent among academics in the IIUM Kuantan campus, particularly among clinical academics during the COVID-19 pandemic and the implementation of remote teaching and learning policy. [ABSTRACT FROM AUTHOR]

Introduction: Poor growth and development can have long-term adverse health impacts, including increased birth defects, impaired cognitive function, and low academic achievement. Essential nutrients, such as omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), offer various health benefits. However, the impact of omega-3 on children's growth is under-researched, with studies typically focusing on single domains like cognitive development. This study aims to review the growth-promoting benefits of omega-3 on children across multiple growth domains. Materials and methods: Following PRISMA guidelines and registered with PROSPERO (CRD42023417580), three databases--PubMed, Scopus, and Cochrane Library--were searched for relevant articles from 2018 to 2022. The Cochrane Risk of Bias Tool for randomized trials (RoB2) was used to assess bias risk, and Mendeley was used to manage and deduplicate articles. Results: Seven randomized clinical trials (RCTs) from 2018 to 2020 were reviewed. Only one study found a significant positive impact of omega-3 on children's cognitive development, while five studies did not. One study explored neurodevelopment, and two RCTs from the UK and Spain examined behavioral outcomes. A study from Indonesia assessed physical growth. Conclusion: Overall, omega-3 fatty acids did not show a significant impact on early childhood development. Omega-3 supplements may enhance behavioral development and physical growth in children but do not significantly affect cognitive or neurodevelopment. [ABSTRACT FROM AUTHOR]

Introduction: This systematic review and meta-analysis aimed to assess the correlations of tear osmolarity (TO) with ocular symptoms and ocular surface parameters in dry eye disease (DED). Materials and methods: A literature search was conducted in PubMed, ScienceDirect, and Google Scholar databases up to 31 December 2022. Observational studies were included if they reported Pearson's-r or Spearman's-ρ of TO with ocular symptoms and/or ocular surface parameter(s) in DED patients without or with other underlying diseases. The r or ρ values were extracted and assessed using a random effect of meta-analysis. Results: Twelve studies were included in the qualitative synthesis and meta- analysis. Overall weighted summary-r values amounted to 0.17, -0.35, and -0.29 for the correlations of TO with ocular symptoms, fluorescein break-up time (FBUT), and Schirmer I, respectively. In the DED subgroup, the weighted summary-r values amounted to 0.11, -0.32, and -0.12 for the correlations of TO with ocular symptoms, FBUT, and Schirmer I, respectively. Greater weighted summary-r values were found in the autoimmune disease-related DED (AID-DED) subgroup for the correlations of TO with ocular symptoms (weighted summary-r, 0.38), FBUT (weighted summary-r, -0.39), Schirmer I (weighted summary-r, -0.47), and corneal staining (weighted summary-r, 0.38). The I2 values were 36% to 92.4%. Conclusion: This systematic review and meta-analysis reveal weak to fair correlations between TO and clinical parameters in DED, with stronger correlations in AID-DED. The findings underscore the need for standardised diagnostic methods and further research to explore the distinct mechanisms of AID-DED. Future studies should focus on longitudinal assessments, advanced diagnostic tools, and patient-centred outcomes to enhance understanding and management of DED, ultimately informing clinical guidelines and improving patient care. [ABSTRACT FROM AUTHOR]

Polyunsaturated fatty acids (PUFAs) intake may be beneficial in many aspects during the early phase of life. This scoping review aims to examine the beneficial outcomes and intakes of omega-3 and omega-6 PUFA among children. An electronic database search on academic journals published from 2017 to 2021 was conducted using Science Direct, PubMed, and Google Scholar. A total of 35 studies were identified and included in this scoping review. Majority of the findings found that PUFAs intake has a beneficial impact on the growth development, mental and cognitive health among children whether they are malnourished, sick or healthy individuals. Overall, this review may provide additional information on the benefits and recommended intake of supplementing PUFAs on children. More detailed research on this topic is needed to support these findings since it will contribute to the formation of the dietary intervention. [ABSTRACT FROM AUTHOR]

Objectives: Clear outcome reporting in clinical trials facilitates accurate interpretation and application of findings and improves evidence-informed decision-making. Standardized core outcomes for reporting neonatal trials have been developed, but little is known about how primary outcomes are reported in neonatal trials. Our aim was to identify strengths and weaknesses of primary outcome reporting in recent neonatal trials., Methods: Neonatal trials including ≥100 participants/arm published between 2015 and 2020 with at least 1 primary outcome from a neonatal core outcome set were eligible. Raters recruited from Cochrane Neonatal were trained to evaluate the trials' primary outcome reporting completeness using relevant items from Consolidated Standards of Reporting Trials 2010 and Consolidated Standards of Reporting Trials-Outcomes 2022 pertaining to the reporting of the definition, selection, measurement, analysis, and interpretation of primary trial outcomes. All trial reports were assessed by 3 raters. Assessments and discrepancies between raters were analyzed., Results: Outcome-reporting evaluations were completed for 36 included neonatal trials by 39 raters. Levels of outcome reporting completeness were highly variable. All trials fully reported the primary outcome measurement domain, statistical methods used to compare treatment groups, and participant flow. Yet, only 28% of trials fully reported on minimal important difference, 24% on outcome data missingness, 66% on blinding of the outcome assessor, and 42% on handling of outcome multiplicity., Conclusions: Primary outcome reporting in neonatal trials often lacks key information needed for interpretability of results, knowledge synthesis, and evidence-informed decision-making in neonatology. Use of existing outcome-reporting guidelines by trialists, journals, and peer reviewers will enhance transparent reporting of neonatal trials., (Copyright © 2023 by the American Academy of Pediatrics.)

Developmental delay, Epilepsy and Neonatal Diabetes (DEND) syndrome is the most severe form of Permanent Neonatal Diabetes with KCNJ11 gene mutation which accounts for most of the cases. We report the first DEND syndrome in Malaysia with heterozygous missense mutation Q52R at KCNJ11 (Kir6.2) gene with delayed presentation beyond 6 months of age and failure to transition to glibenclamide. This report signifies the phenotypical variability among patients with the same genetic mutation and the different response to treatment., (© 2020 Journal of the ASEAN Federation of Endocrine Societies.)